Alain Commercon

This inventor holds 40 USPTO granted patents and 4 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Anticancer Agents. Top assignees: Rhone-Poulenc Rorer S.a., Aventis Pharma S.a., Sanofi. Active years: 1995-2017.

USPTO Granted Patents = 40 (Patent Applications = 4)

% Patents Active = 87.5

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 5)

Average Co-Inventor Count = 3.2

ph-index = 13

Forward Citations = 665(Granted Patents)

Location History:

Virty-Sur-Seine, FR (1996)
Vitry, FR (2003)
Paris, FR (2015)
Vitry sur Seine, FR (1995 - 2017)

Company Filing History:

23 out of 247

Rhone-Poulenc Rorer S.a.

Aventis Pharma Limited

patents

6. 1 out of 1

Phone-Poulenc Rorer Sa.

patent

7. 2 out of 834,307

Other

patents

Years Active: 1995-2017

Loading Chart...

Areas of Expertise:

EphA2 Receptor

Antibodies

Cytotoxic Agents

Taxoids

Farnesyl Transferase Inhibitors

Pyrrolo[1,4]Benzodiazepine

Polyhydroxypyrazine

Medicinal Products

Pharmaceutical Compositions

Leptomycin Derivatives

Indazoles

Baccatin III

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9676864 - Antibodies that specifically bind to the EphA2 receptor (2017-06-13),

2. 9056914 - Anticancer derivatives, preparation thereof and therapeutic use thereof (2015-06-16),

3. 8952147 - Conjugates, preparation thereof, and therapeutic use thereof (2015-02-10),

4. 8668910 - Antibodies that specifically bind to the EphA2 receptor (2014-03-11),

5. 8481042 - Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents (2013-07-09),

6. 8163736 - Cytotoxic agents comprising new tomaymycin derivatives (2012-04-24),

7. 7816543 - Leptomycin derivatives (2010-10-19),

8. 7667054 - Cytotoxic agents comprising new taxanes (2010-02-23),

9. 7491710 - Organophosphorus derivatives of indazoles and use thereof as medicinal products (2009-02-17),

10. 7074821 - Taxoids, their preparation and pharmaceutical composition containing them (2006-07-11),

11. 6818637 - Polyhydroxypyrazine derivatives, their preparation and the pharmaceutical compositions which comprise them (2004-11-16),

12. 6632814 - Dihydro-benzo(1,4)oxazines (2003-10-14),

13. 6608084 - Aza-bicycles which modulate the inhibition of cell adhesion (2003-08-19),

14. 6548533 - Ureido substituted pyrrolidines (2003-04-15),

15. 6384071 - Taxoids, their preparation and pharmaceutical compositions containing them (2002-05-07),

Title: Innovations and Contributions of Alain Commercon

Introduction: Alain Commercon, based in Vitry-sur-Seine, France, is a notable inventor with a significant contribution to the field of biomedicine. With a remarkable portfolio of 40 patents, he specializes in the development of antibody-based therapies aimed at addressing critical health issues, particularly in cancer treatment.

Latest Patents: Among his latest inventions, Commercon has developed innovative antibodies that specifically bind to the EphA2 receptor. This patent describes an antibody or an epitope-binding fragment capable of targeting the EphA2 receptor, along with a conjugate that includes a cytotoxic agent covalently bound to the antibody. Another noteworthy patent details anticancer derivatives, preparing them, and their therapeutic applications, showcasing his commitment to advancing cancer therapies.

Career Highlights: Alain Commercon has built a significant career in the pharmaceutical industry, notably with companies such as Rhone-Poulenc Rorer S.A. and Aventis Pharma S.A. His extensive work in these organizations has allowed him to develop valuable innovations that contribute to both scientific knowledge and therapeutic advancements.

Collaborations: Throughout his professional journey, Commercon has collaborated with various expert colleagues, including Jean-Dominique Bourzat and Herve Bouchard. These partnerships have facilitated a productive exchange of ideas and further enriched the quality of his innovations.

Conclusion: Alain Commercon stands out in the realm of biomedicine through his substantial patent portfolio and collaborative spirit. His inventions, particularly in the field of antibody therapies, reflect a dedication to improving cancer treatment methodologies, leaving a lasting impact on both the scientific community and patient care.